News

The funding has been allotted to spend over five years across eight CTUs in Cardiff, Birmingham, Glasgow, Southampton, Leeds and London. The CTUs are engaged in the designing, delivery

NF1 is an incurable genetic condition that affects one in 3,000 births, with highly-variable symptoms, including cutaneous (skin), neurological (nervous system) and orthopaedic (skeletal) manifestations. NF1 can cause

Fluarix Tetra has been approved in Europe to include adults and now children from six months of age for the prevention of influenza disease caused by the two

Headquartered in New York, Flatiron Health is a provider of oncology-specific electronic health record (EHR) software. The company, which was founded in 2012, is also engaged into curation

The proceeds from the commitment will be used to refinance Veloxis's outstanding debt, accelerate the growth of Envarsus XR in the US and help fund working capital of

The transaction adds the Universal Donor Cell technology to Astellas Pharma with which it will create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching,

The FDA approval secured by the Johnson & Johnson (J&J) subsidiary comes after last week’s results of the phase 3 SPARTAN trial in patients with NM-CRPC in which

The trial included a placebo arm and an active control arm (adalimumab) for comparison with placebo, and studied patients who had never received a biologic disease-modifying anti-rheumatic drug

The programs will leverage CureVac’s RNActive prophylactic vaccine technology to develop mRNA-based vaccines designed to prevent influenza and malaria infection. These vaccines, which are flexible in their applications,